Antoine Italiano

78PUBLICATIONS
627CO-AUTHORS
Molecular targetsEndodonticsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (78)

|Aug 11, 2026
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.

|Jul 29, 2026
Deni Study: Real-World Data on the Use of Nirogacestat in Patients With Desmoid Tumors in the French Sarcoma Group.

|Jul 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

|Jun 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

|Jun 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

|Jun 08, 2026
Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors.

Pageof 13

Frequent Collaborators

14 joint publications

Jean-Yves Blay

8 joint publications

Benjamin Besse

7 joint publications

Damien Vasseur

6 joint publications

Antoine Hollebecque